Patents by Inventor Marianne Bronner

Marianne Bronner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132882
    Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the triggerbinding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.
    Type: Application
    Filed: December 12, 2023
    Publication date: April 25, 2024
    Inventors: Lisa Hochrein, Mikhail H. Hanewich-Hollatz, Zhewei Chen, Heyun Li, Shashank Gandhi, Marianne Bronner, Niles A. Pierce
  • Patent number: 11873485
    Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: January 16, 2024
    Assignee: California Institute of Technology
    Inventors: Lisa Hochrein, Mikhail H. Hanewich-Hollatz, Zhewei Chen, Heyun Li, Shashank Gandhi, Marianne Bronner, Niles A. Pierce
  • Publication number: 20220348909
    Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.
    Type: Application
    Filed: January 25, 2022
    Publication date: November 3, 2022
    Inventors: Lisa Hochrein, Mikhail H. Hanewich-Hollatz, Zhewei Chen, Heyun Li, Shashank Gandhi, Marianne Bronner, Niles A. Pierce
  • Patent number: 8907073
    Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: December 9, 2014
    Assignee: California Institute of Technology
    Inventors: Tatjana Sauka-Spengler, Sonja Jane McKeown, Paola A. Betancur, Marianne Bronner Hansen
  • Publication number: 20130273596
    Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Inventors: Tatjana Sauka-Spengler, Sonja J. McKeown, Paola Betancur, Marianne Bronner
  • Patent number: 8524875
    Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 3, 2013
    Assignee: California Institute of Technology
    Inventors: Tatjana Sauka-Spengler, Sonja J. McKeown, Paola Betancur, Marianne Bronner
  • Publication number: 20100311048
    Abstract: DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells.
    Type: Application
    Filed: December 22, 2009
    Publication date: December 9, 2010
    Inventors: Tatjana Sauka-Spengler, Sonja J. McKeown, Paola Betancur, Marianne Bronner-Fraser